Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, explores emerging therapies for patients with myelofibrosis including pacritinib and momelotinib, JAK kinase inhibitors, as well as other agents therapies being investigated as single agents or as part of combined approaches. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).